Stockscreener 앱 받기
19.92
0.41%
0.22
전일 마감가:
$19.70
열려 있는:
$19.699
하루 거래량:
43,225
Relative Volume:
0.27
시가총액:
$174.22M
수익:
$123.24M
순이익/손실:
$136.00K
주가수익비율:
-996.00
EPS:
-0.02
순현금흐름:
$-148.99M
1주 성능:
+0.72%
1개월 성능:
+26.08%
6개월 성능:
+114.09%
1년 성능:
+21.29%
1일 변동 폭
$19.55
$20.85
1주일 범위
$18.54
$20.85
52주 변동 폭
$6.53
$24.67
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
MCRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
19.90 | 172.47M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.12 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
480.15 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.60 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
818.45 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
317.88 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-08 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Is Seres Therapeutics Inc. stock a contrarian buyQuarterly Profit Review & Community Verified Swing Trade Signals - newser.com
Seres Therapeutics (MCRB) to Present New Phase 1b Trial Data at IDWeek 2025 - GuruFocus
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant - The Manila Times
Seres Therapeutics Presents 77% BSI Reduction in SER-155 Phase 1b | MCRB Stock News - Stock Titan
How Seres Therapeutics Inc. (1S90) stock moves on employment dataMarket Performance Recap & Stock Timing and Entry Methods - newser.com
News impact scoring models applied to Seres Therapeutics Inc.CPI Data & Fast Gaining Stock Strategy Reports - newser.com
Vontobel Holding Ltd. Has $892,000 Holdings in Seres Therapeutics, Inc. $MCRB - MarketBeat
Will Seres Therapeutics Inc. stock benefit from infrastructure spendingMarket Performance Report & High Accuracy Trade Alerts - newser.com
Is Seres Therapeutics Inc. stock supported by innovation pipelineMarket Movement Recap & Consistent Profit Trade Alerts - newser.com
Seres Therapeutics soars on report of takeover offer - MSN
Exit strategy if you’re trapped in Seres Therapeutics Inc.Weekly Trading Summary & Expert Verified Movement Alerts - newser.com
Is Seres Therapeutics Inc. forming a bottoming baseTreasury Yields & Long-Term Growth Plans - newser.com
Can you recover from losses in Seres Therapeutics Inc.Weekly Stock Recap & AI Powered Trade Plan Recommendations - newser.com
Quantitative breakdown of Seres Therapeutics Inc. recent moveCPI Data & Stepwise Swing Trade Plans - newser.com
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
Is it too late to sell Seres Therapeutics Inc.2025 Winners & Losers & Detailed Earnings Play Strategies - newser.com
Seres Therapeutics (NASDAQ:MCRB) Receives "Sell (D+)" Rating from Weiss Ratings - MarketBeat
Building trade automation scripts for Seres Therapeutics Inc.July 2025 Macro Moves & High Return Trade Opportunity Guides - newser.com
Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Target Price at $14.33 - Defense World
Technical signs of recovery in Seres Therapeutics Inc.July 2025 Trends & Verified Momentum Watchlists - newser.com
Seres Therapeutics Inc. stock retracement – recovery analysisMarket Rally & Free Risk Controlled Daily Trade Plans - newser.com
How high can Seres Therapeutics Inc. stock goMarket Activity Summary & Daily Momentum Trading Reports - newser.com
Published on: 2025-10-05 04:28:16 - newser.com
Understanding Seres Therapeutics Inc.’s price movementJuly 2025 PostEarnings & Pattern Based Trade Signal System - newser.com
Is Seres Therapeutics Inc. a candidate for recovery playJuly 2025 Update & Daily Entry Point Alerts - newser.com
Seres Therapeutics announces workforce reduction to extend cash runway - Investing.com
Seres Therapeutics Cuts Costs to Extend Cash Runway - TipRanks
Dated alerts on Seres Therapeutics' measures to cut costs withdrawn - MarketScreener
Developing predictive dashboards with Seres Therapeutics Inc. dataWeekly Earnings Recap & AI Enhanced Trading Signals - newser.com
Using data tools to time your Seres Therapeutics Inc. exit2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
Published on: 2025-10-03 00:05:20 - newser.com
Is Seres Therapeutics Inc a good long term investmentShort-Term Trading Alerts & Outperform the Market with Aggressive Picks - earlytimes.in
Goldman Sachs Group Inc. Acquires 21,679 Shares of Seres Therapeutics, Inc. $MCRB - MarketBeat
What analysts say about Seres Therapeutics Inc stockInstitutional Holding Changes & Capitalize On Fast Trends - earlytimes.in
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.77%
0.72%
자본화:
|
볼륨(24시간):